Paltusotine ( CRN-00808 )
Catalog No: 20294
CAS Number: 2172870-89-0
Purity: ≧98.0%
Paltusotine is a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonists designed for the treatment of acromegaly.
For research use only. We do not sell to patients.
Chemical Information
| Name | Paltusotine ( CRN-00808 ) |
|---|---|
| Iupac Chemical Name | 3-[4-(4-aminopiperidin-1-yl)-3-(3,5- difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile |
| Synonyms | Paltusotine ; CRN00808 ; CRN-00808 ; CRN 00808 ; |
| Molecular Formula | C27H22F2N4O |
| Molecular Weight | 456.49 |
| Smile | N#CC1=CC=CC(C2=CC=C3N=CC(C4=CC(F)=CC(F)=C4)=C(N5CCC(N)CC5)C3=C2)=C1O |
| InChiKey | GHILNKWBALQPDP-UHFFFAOYSA-N |
| InChi | InChI=1S/C27H22F2N4O/c28-19-10-18(11-20(29)13-19)24-15-32-25-5-4-16(22-3-1-2-17(14-30)27(22)34)12-23(25)26(24)33-8-6-21(31)7-9-33/h1-5,10-13,15,21,34H,6-9,31H2 |
| CAS Number | 2172870-89-0 |
| Related CAS | 2361216-83-1 (HCl) ; 2172870-89-0 (free base) ; 2172875-40-8 (2HCl) |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | ≧98.0% |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | Refer to MSDS operation |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
Coming soon.
| Targets | ORAL SST2 AGONIST |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
[1]. Murray B. Gordon, et al. Identification of a dose range for once daily oral paltusotine in patients with acromegaly that maintains IGF-1 levels when switching from long-acting somatostatin receptor ligand therapy. Endocrine Abstracts (2021) 73 OC15.4.
[2]. Rosa Luo, et al. Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly. Journal of the Endocrine Society, Volume 5, Issue Supplement_1, April-May 2021.
Chemical Structure
